AxoGen, Inc.
AXGNNASDAQHealthcare● Active
$42.05
$-0.75(-1.74%)
Market Cap$2.2B
P/E Ratio—
52W High$45.83
52W Low$9.22
AxoGen, Inc. (AXGN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AXGN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 28, 2026EPS Actual
$0.07
Est. $0.12 · -41.7%
Revenue
$0.06B
Est. $0.06B · +6.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 28, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
AXGN reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.09 | — | — | — | $0.07B | — |
| ▼ Q2 FY2026 | Apr 28, 2026 | $0.12 | $0.07 | -41.7% | $0.06B | $0.06B | +6.2% |
| ▼ Q1 FY2026 | Feb 24, 2026 | $0.09 | $0.07 | -21.2% | $0.06B | $0.06B | +1.5% |
| ▲ Q4 FY2025 | Oct 29, 2025 | $0.09 | $0.12 | +33.3% | $0.06B | $0.06B | +0.3% |
| ▲ Q3 FY2025 | Aug 5, 2025 | $0.06 | $0.12 | +100.0% | $0.06B | $0.06B | -0.4% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.01 | -$0.02 | -100.0% | $0.05B | $0.05B | -9.0% |
| ▲ Q1 FY2025 | Feb 25, 2025 | $0.04 | $0.08 | +100.0% | $0.05B | $0.05B | +2.3% |
| ▲ Q4 FY2024 | Nov 7, 2024 | $0.01 | $0.07 | +1066.7% | $0.05B | $0.05B | +2.5% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.09
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 28, 2026Miss
EPS Actual
$0.07
EPS Est.
$0.12
EPS Surpr.
-41.7%
Revenue
$0.06B
Q1 FY2026
Feb 24, 2026Miss
EPS Actual
$0.07
EPS Est.
$0.09
EPS Surpr.
-21.2%
Revenue
$0.06B
Q4 FY2025
Oct 29, 2025Beat
EPS Actual
$0.12
EPS Est.
$0.09
EPS Surpr.
+33.3%
Revenue
$0.06B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
$0.12
EPS Est.
$0.06
EPS Surpr.
+100.0%
Revenue
$0.06B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.02
EPS Est.
-$0.01
EPS Surpr.
-100.0%
Revenue
$0.05B
Q1 FY2025
Feb 25, 2025Beat
EPS Actual
$0.08
EPS Est.
$0.04
EPS Surpr.
+100.0%
Revenue
$0.05B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
$0.07
EPS Est.
$0.01
EPS Surpr.
+1066.7%
Revenue
$0.05B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.23 | $0.23 | $0.24 | 2 |
| Q3 FY2027 | $0.21 | $0.22 | $0.22 | 1 |
| Q2 FY2027 | $0.20 | $0.20 | $0.20 | 1 |
| Q1 FY2027 | $0.17 | $0.17 | $0.17 | 2 |
| Q4 FY2026 | $0.15 | $0.15 | $0.15 | 2 |
| Q3 FY2026 | $0.14 | $0.14 | $0.15 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 2 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 28, 2026 | -41.7% | $39.39 | $41.99 | +6.60% |
| ▼ Q1 FY2026 | Feb 24, 2026 | -21.2% | $35.38 | $32.50 | -8.14% |
| ▲ Q4 FY2025 | Oct 29, 2025 | +33.3% | $18.08 | $22.25 | +23.06% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +100.0% | $12.55 | $13.72 | +9.32% |
| ▼ Q2 FY2025 | May 8, 2025 | -100.0% | $16.39 | $12.59 | -23.18% |
| ▲ Q1 FY2025 | Feb 25, 2025 | +100.0% | $18.01 | $20.11 | +11.66% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +1066.7% | $15.33 | $13.27 | -13.44% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +200.0% | $7.92 | $10.70 | +35.10% |
Q2 FY2026+6.60%
Report Date
Apr 28, 2026
EPS Beat/Miss
-41.7%
Price Before
$39.39
Price After
$41.99
Q1 FY2026-8.14%
Report Date
Feb 24, 2026
EPS Beat/Miss
-21.2%
Price Before
$35.38
Price After
$32.50
Q4 FY2025+23.06%
Report Date
Oct 29, 2025
EPS Beat/Miss
+33.3%
Price Before
$18.08
Price After
$22.25
Q3 FY2025+9.32%
Report Date
Aug 5, 2025
EPS Beat/Miss
+100.0%
Price Before
$12.55
Price After
$13.72
Q2 FY2025-23.18%
Report Date
May 8, 2025
EPS Beat/Miss
-100.0%
Price Before
$16.39
Price After
$12.59
Q1 FY2025+11.66%
Report Date
Feb 25, 2025
EPS Beat/Miss
+100.0%
Price Before
$18.01
Price After
$20.11
Q4 FY2024-13.44%
Report Date
Nov 7, 2024
EPS Beat/Miss
+1066.7%
Price Before
$15.33
Price After
$13.27
Q3 FY2024+35.10%
Report Date
Aug 8, 2024
EPS Beat/Miss
+200.0%
Price Before
$7.92
Price After
$10.70
Avg Beat Reaction+13.14%
Avg Miss Reaction-8.24%
Beat Rate5 / 8 quarters
Largest Move+35.10% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AXGN ends December
AxoGen, Inc. (AXGN) most recently reported earnings on April 28, 2026 for Q2 FY2026, posting EPS of $0.07 — missing the analyst consensus of $0.12 by -41.7%. The next AXGN earnings date is expected around September 1, 2026.
Each quarter, investors track AXGN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AXGN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AXGN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AXGN earnings · 5 questionsAxoGen, Inc.'s next earnings report is expected around September 1, 2026. AXGN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AXGN historically reports after market close (AMC).
AXGN earnings datewhen is AXGN earningsAXGN next earnings datewhen does AXGN report earningsAXGN earnings calendar
▸ Source: FMP · AxoGen, Inc. SEC filings · US GAAP · AxoGen, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026